FidoCure Veterinary Team Blog

Lucas Rodrigues, DVM, MS, PhD
Head of Veterinary Research at FidoCure

Precision medicine has revolutionized human oncology by enabling treatments tailored to the unique genetic makeup of each tumor. Now, this same approach is being increasingly adopted in veterinary medicine, bringing a new level of sophistication to cancer care in dogs. Small molecule targeted therapies are at the forefront of this movement, offering the potential for more effective and individualized treatments. However, their success depends on a critical first step: identifying the genetic drivers behind each tumor. Without this information, the use of targeted therapies becomes a gamble, especially risky in aggressive cancers with diverse genetic profiles, where delays in effective treatment can have serious consequences.

Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript "Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics," recently published in Scientific Reports.

In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.

Genetic Signatures in Canine Mammary Tumors: insights from BRCA1 mutations